- To establish whether a reduced dose of rivaroxaban significantly decreased the composite outcome in patients on hemodialysis with atrial fibrillation.
- To determine clinical significance of study results.
05/21/2021 - 12:00pm to 1:00pm CDT
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Anand Narayanan, MD